Chapsal B, Kimbrough J, Bester S, Bergstrom A, Backos D, Campos B
ACS Med Chem Lett. 2025; 16(2):224-233.
PMID: 39967615
PMC: 11831402.
DOI: 10.1021/acsmedchemlett.4c00311.
Lisi-Vega L, Pievani A, Garcia-Fernandez M, Forte D, Williams T, Serafini M
Cell Rep. 2025; 44(1):115151.
PMID: 39932190
PMC: 7617453.
DOI: 10.1016/j.celrep.2024.115151.
Able M, Kasper M, Vick B, Schwach J, Gao X, Schmitt S
Leukemia. 2025; 39(3):632-642.
PMID: 39870768
PMC: 11879846.
DOI: 10.1038/s41375-024-02510-5.
Fei F, Telatar M, Tomasian V, Chang L, Gust M, Yew H
Int J Mol Sci. 2025; 26(2).
PMID: 39859151
PMC: 11765404.
DOI: 10.3390/ijms26020435.
Liapodimitri A, Tetens A, Craig-Schwartz J, Lunsford K, Skalitzky K, Koldobskiy M
Cancers (Basel). 2025; 16(24.
PMID: 39766049
PMC: 11674401.
DOI: 10.3390/cancers16244149.
DOT1L Mediates Stem Cell Maintenance and Represents a Therapeutic Vulnerability in Cancer.
Kurani H, Kurani H, Slingerland J
Cancer Res. 2024; 85(5):838-847.
PMID: 39700409
PMC: 11873724.
DOI: 10.1158/0008-5472.CAN-24-3304.
Fusion Genes in Myeloid Malignancies.
Ang C, Than H, Tuy T, Goh Y
Cancers (Basel). 2024; 16(23).
PMID: 39682241
PMC: 11639841.
DOI: 10.3390/cancers16234055.
Getting the right combination to break the epigenetic code.
Tolu S, Viny A, Amengual J, Pro B, Bates S
Nat Rev Clin Oncol. 2024; 22(2):117-133.
PMID: 39623073
DOI: 10.1038/s41571-024-00972-1.
Targeting chromatin modifying complexes in acute myeloid leukemia.
Schurer A, Glushakow-Smith S, Gritsman K
Stem Cells Transl Med. 2024; 14(2).
PMID: 39607901
PMC: 11878770.
DOI: 10.1093/stcltm/szae089.
Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions.
Dhiman S, Dhillon V, Balasubramanian S
Cancers (Basel). 2024; 16(22).
PMID: 39594699
PMC: 11592310.
DOI: 10.3390/cancers16223743.
Multi-omic analysis of longitudinal acute myeloid leukemia patient samples reveals potential prognostic markers linked to disease progression.
Ahmed N, Cavattoni I, Villiers W, Cugno C, Deola S, Mifsud B
Front Genet. 2024; 15:1442539.
PMID: 39399221
PMC: 11466779.
DOI: 10.3389/fgene.2024.1442539.
Menin in Cancer.
Majer A, Hua X, Katona B
Genes (Basel). 2024; 15(9).
PMID: 39336822
PMC: 11431421.
DOI: 10.3390/genes15091231.
Drug Repurposing Approach to Identify Candidate Drug Molecules for Hepatocellular Carcinoma.
Baser T, Rifaioglu A, Atalay M, Cetin Atalay R
Int J Mol Sci. 2024; 25(17).
PMID: 39273340
PMC: 11395636.
DOI: 10.3390/ijms25179392.
Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives.
Guarnera L, DAddona M, Bravo-Perez C, Visconte V
Int J Mol Sci. 2024; 25(16).
PMID: 39201709
PMC: 11354696.
DOI: 10.3390/ijms25169023.
Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia.
Shukla M, Abdul-Hay M, Choi J
Biomedicines. 2024; 12(8).
PMID: 39200232
PMC: 11351617.
DOI: 10.3390/biomedicines12081768.
A potent and selective ENL degrader suppresses oncogenic gene expression and leukemia progression.
Xue Z, Qin L, Xuan H, Luo K, Huang M, Xie L
Sci Adv. 2024; 10(35):eado1432.
PMID: 39196923
PMC: 11352836.
DOI: 10.1126/sciadv.ado1432.
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.
Cuglievan B, Kantarjian H, Rubnitz J, Cooper T, Zwaan C, Pollard J
Leukemia. 2024; 38(10):2073-2084.
PMID: 39179671
PMC: 11436367.
DOI: 10.1038/s41375-024-02368-7.
Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia.
Zhou X, Zhang L, Aryal S, Veasey V, Tajik A, Restelli C
Blood. 2024; 144(19):2018-2032.
PMID: 39158067
PMC: 11561541.
DOI: 10.1182/blood.2023023644.
Revumenib for patients with acute leukemia: a new tool for differentiation therapy.
Yisraeli Salman M, Stein E
Haematologica. 2024; 109(11):3488-3495.
PMID: 39086307
PMC: 11532683.
DOI: 10.3324/haematol.2022.282621.
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
Hernandez-Sanchez A, Gonzalez T, Sobas M, Strang E, Castellani G, Abaigar M
Leukemia. 2024; 38(9):1929-1937.
PMID: 38965370
PMC: 11347382.
DOI: 10.1038/s41375-024-02333-4.